Study Shows Patients Vaccinated Against Ebola Are Half as Likely to Die Than Unvaccinated Patients
A new study showed patients with confirmed Ebola virus disease were half as likely to die if they were vaccinated against the virus than if they were not.
FDA Approves First Cell Therapy to Treat Melanoma
FDA approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with unresectable melanoma or metastatic melanoma that previously has been treated with other therapies.
Third Humira Biosimilar Is Approved by FDA
FDA has approved Alvotech’s Simlandi (adalimumab-ryvk) as the third interchangeable Humira biosimilar.
CMS Finalizes Rule to Advance Health Equity
CMS finalized policies to support primary care, advance health equity, assist family caregivers and expand access to behavioral and certain oral healthcare.
$13M NIH Grant Funds Research to Rejuvenate Immune System in Older Adults
University of Arizona Health Sciences researchers have received a $13.1 million grant from the National Institute on Aging to continue studies aimed at rejuvenating the immune system of older people to improve health throughout the lifespan.
New Guidance Recommends All Federal Facilities Have Access to Naloxone
The U.S. Department of Health and Human Services and the General Services Administration have announced new guidance recommending that all federal facilities across the nation include overdose reversal medications in their safety stations on site.
FDA Approves Zepbound to Treat Obstructive Sleep Apnea
The U.S. Food and Drug Administration has authorized the use of Eli Lilly & Co.’s Zepbound for adults with obesity and moderate to severe obstructive sleep apnea, a common condition where a person struggles to breathe properly during sleep.
FDA Expands Approval to wilate for Prophylaxis in All Types of VWDr
Octapharma USA’s wilate, von Willebrand factor (VWF)/coagulation factor VIII complex (human) lyophilized power for solution for intravenous injection, has been given expanded approval by the U.S. Food and Drug Administration (FDA) for routine prophylaxis to reduce the frequency of bleeding episodes in adults and children aged 6 and older with any type of von Willebrand disease (VWD).
Hyaluronidase-Facilitated Subcutaneous Immune Globulin Effective as Maintenance Therapy for CIDP: Pivotal Trial Results
In a study, researchers found that fSCIG 10% was more effective in preventing CIDP relapse than placebo, supporting its potential use as maintenance CIDP treatment.
Outpatient Albumin Infusions Reduce Hospitalizations in Decompensated Cirrhosis: Retrospective Cohort Study
A team of Australian investigators conducted a retrospective cohort study to determine whether there is a significant benefit in more severely affected cases regularly infused with albumin.